Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $348.00 million. The enterprise value is $134.70 million.
Important Dates
The next estimated earnings date is Sunday, February 16, 2025, before market open.
Earnings Date | Feb 16, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CTNM has 25.78 million shares outstanding. The number of shares has increased by 488.88% in one year.
Current Share Class | 19.05M |
Shares Outstanding | 25.78M |
Shares Change (YoY) | +488.88% |
Shares Change (QoQ) | +10.17% |
Owned by Insiders (%) | 1.51% |
Owned by Institutions (%) | 32.65% |
Float | 13.13M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.65 |
P/TBV Ratio | 1.66 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 37.06, with a Debt / Equity ratio of 0.00.
Current Ratio | 37.06 |
Quick Ratio | 36.84 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.76% and return on invested capital (ROIC) is -15.84%.
Return on Equity (ROE) | -20.76% |
Return on Assets (ROA) | -15.32% |
Return on Capital (ROIC) | -15.84% |
Revenue Per Employee | n/a |
Profits Per Employee | -$931,839 |
Employee Count | 31 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -161,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 15.77 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 38.51 |
Average Volume (20 Days) | 134,329 |
Short Selling Information
The latest short interest is 1.04 million, so 4.03% of the outstanding shares have been sold short.
Short Interest | 1.04M |
Short Previous Month | 1.05M |
Short % of Shares Out | 4.03% |
Short % of Float | 7.90% |
Short Ratio (days to cover) | 20.60 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -43.52M |
Pretax Income | n/a |
Net Income | -28.89M |
EBITDA | -43.30M |
EBIT | -43.52M |
Earnings Per Share (EPS) | -$2.14 |
Full Income Statement Balance Sheet
The company has $213.91 million in cash and $611,000 in debt, giving a net cash position of $213.30 million or $8.27 per share.
Cash & Cash Equivalents | 213.91M |
Total Debt | 611,000 |
Net Cash | 213.30M |
Net Cash Per Share | $8.27 |
Equity (Book Value) | 210.23M |
Book Value Per Share | 8.17 |
Working Capital | 209.34M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$33.35 million and capital expenditures -$657,000, giving a free cash flow of -$34.00 million.
Operating Cash Flow | -33.35M |
Capital Expenditures | -657,000 |
Free Cash Flow | -34.00M |
FCF Per Share | -$1.32 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CTNM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -488.88% |
Shareholder Yield | -488.88% |
Earnings Yield | -8.30% |
FCF Yield | -9.77% |
Analyst Forecast
The average price target for CTNM is $29.25, which is 116.67% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $29.25 |
Price Target Difference | 116.67% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
CTNM has an Altman Z-Score of 46.66 and a Piotroski F-Score of 1.
Altman Z-Score | 46.66 |
Piotroski F-Score | 1 |